UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/827,480	04/19/2004	Cassandre Michelle Fecht	DC4998CIP1	3304
Dow Corning C	7590 09/13/201 Corporation	EXAMINER		
Intellectual Prop	perty Dept CO1232	ROBERTS, LEZAH		
P.O. Box 994 Midland, MI 48686-0994			ART UNIT	PAPER NUMBER
,			1612	
			MAIL DATE	DELIVERY MODE
			09/13/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/827,480	FECHT ET AL.		
Examiner	Art Unit		
LEZAH W. ROBERTS	1612		

	LEZAH W. ROBERTS	1612				
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress			
THE REPLY FILED <u>05 August 2010</u> FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.						
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apper for Continued Examination (RCE) in compliance with 37 Coperiods:	the same day as filing a Notice of replies: (1) an amendment, affidate eal (with appeal fee) in compliance FR 1.114. The reply must be filed	Appeal. To avoid abarrit, or other evidence, we with 37 CFR 41.31; or	which places the r (3) a Request			
<ul> <li>a)</li></ul>	dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailin b). ONLY CHECK BOX (b) WHEN TH f).	ng date of the final rejection E FIRST REPLY WAS FI	on. LED WITHIN TWO			
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount hortened statutory period for reply orig than three months after the mailing da	of the fee. The appropria	ate extension fee be action; or (2) as			
2. The Notice of Appeal was filed on <u>August 5, 2010</u> . A bried date of filing the Notice of Appeal (37 CFR 41.37(a)), or a Since a Notice of Appeal has been filed, any reply must be <u>AMENDMENTS</u>	ny extension thereof (37 CFR 41.3	37(e)), to avoid dismiss	al of the appeal.			
3. The proposed amendment(s) filed after a final rejection, to (a) They raise new issues that would require further core (b) They raise the issue of new matter (see NOTE belo (c) They are not deemed to place the application in bet appeal; and/or	nsideration and/or search (see NC w); ter form for appeal by materially re	TE below); educing or simplifying t				
(d) They present additional claims without canceling a convergence NOTE: (See 37 CFR 1.116 and 41.33(a)).  4. The amendments are not in compliance with 37 CFR 1.12  5. Applicant's reply has overcome the following rejection(s):	21. See attached Notice of Non-Co	ompliant Amendment (				
<ul> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> <li>For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prove The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1.2,5-7,9,11 and 12.</li> </ul>	☐ will not be entered, or b) ☐ w	•	_			
Claim(s) withdrawn from consideration: <u>13 and 14</u> .						
AFFIDAVIT OR OTHER EVIDENCE  8. The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).						
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).						
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.  REQUEST FOR RECONSIDERATION/OTHER						
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:  See Continuation Sheet.						
12. Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s)13. Other:						
/Frederick Krass/ Supervisory Patent Examiner, Art Unit 1612	/Lezah W Roberts/ Examiner, Art Unit 1612	2				

Continuation of 11. does NOT place the application in condition for allowance because: Applicant argues that Candau and Lemann at best disclose a chemical formula that represents a genus of the present hydrocarbyl functional organopolysiloxanes. Applicant further argues that MPEP 2144.08 should be used in assessing obviousness of genus/sub-genus/species relationships and not In re Peterson as used in the standing rejection.

The Examiner submits that in regard to using 2144.08 to determine obviousness, this has been considered as well as using In re Peterson. The office action specifically discusses how the compounds of the instant claims are encompassed by the compounds of both references. This is discussed in detail in the previous office actions. The scope and contents of the prior art was discussed; the differences were ascertained between the prior art and the claims in issue; the level of skill is one of ordinary skill in the art; and Applicant does not appear to have provided or pointed to any evidence of secondary consideration to support why the compounds recited by the instant claims are nonobvious over those disclosed by the two references. Further the claims read on a composition comprising a cosmetic ingredient, a household care ingredient or a health care ingredient, thus the claims recite the same intended use for the recited compounds as that disclosed by the references. Further obviousness was supported by In re Peterson, which discloses overlapping ranges are obvious. The number of units of each functional group in the reference overlapped those corresponding units of the instant claims and thus the reference encompasses the instant claims.